All-trans-retinoic acid treatment for chemotherapy-resistant acute adult T-cell leukemia.
We report a case in which treatment with all-trans-retinoic acid (ATRA) improved the clinical features of a 47-year-old female patient with acute adult T-cell leukemia (ATL). The patient was first treated several times with combination chemotherapy. but the number of ATL cells increased and other clinical manifestations progressed. ATRA 60 mg was then administered daily. ATRA treatment dramatically improved the patient's clinical features. In vitro examination revealed that ATRA inhibited the growth of ATL cells from the patient. These findings suggest that ATRA may be a useful treatment for patients with chemotherapy-resistant acute ATL.
Toshima
M
M
Department of Hematology, Jichi Medical School, Tochigi, Japan.
Nagai
T
T
Izumi
T
T
Tarumoto
T
T
Takatoku
M
M
Imagawa
S
S
Komatsu
N
N
Ozawa
K
K
D000208:Acute Disease; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D015458:Leukemia, T-Cell / Q000188:drug therapy* / Q000473:pathology; D008875:Middle Aged; D014212:Tretinoin / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D014212:Tretinoin